Introduction {#Sec1}
============

The common trend of combining the adolescents and young adults (AYA) with cancer, defined here as persons diagnosed between 15 and 39 years of age at time of diagnosis \[[@CR1]\], with either pediatric or older adult cancer populations in psychosocial research has created a gap in understanding the cancer experience of AYAs \[[@CR2]\]. Adolescence and young adulthood are life stages characterized by increased vulnerability to stress as age-related developmental tasks need to be achieved \[[@CR3], [@CR4]\], such as completing school and becoming independent from parents for adolescents and starting a family and getting a mortgage for young adults. A cancer diagnosis challenges AYAs' abilities to achieve these developmental milestones \[[@CR5]\] and can compromise AYAs' adjustment and health-related quality of life (HRQoL) \[[@CR6]\].

Much of today's psychosocial oncology research harkens to Selye's theoretical stress and coping models, in which human emotional response to upsetting or traumatic events or conditions may be experienced as "distress" (negative) or "eustress" (positive) \[[@CR7]\]. Subsequent applications of stress coping theory to investigations of patients' psychosocial adaptation to cancer suggest that it is theoretically possible to experience both positive and negative responses to cancer simultaneously. Tedeschi and Calhoun have conceptualized positive adaptation to traumatic life events, including serious illness, as posttraumatic growth (PTG) \[[@CR8], [@CR9]\]. Positive changes reported by some cancer survivors have included a greater sense of closeness to others, higher appreciation of everyday life, recognition of new possibilities in life, a sense of personal strength, and deeper spirituality \[[@CR10]\]. In a semi-structured interview study of AYAs' diagnosed and treated for cancer \[[@CR11]\], two recurrent themes emerged: (1) loss of control resulting in a sense of frustration and anger and (2) benefit finding such as improved personal attributes and strengthened relationships. All but one participant reported that they experienced at least one positive aspect of being treated for cancer. Quantitative research examining the prevalence of PTG in AYA cancer populations is scarce but suggests that most AYA cancer patients report some PTG \[[@CR12]--[@CR16]\].

There is controversy in the literature about how to conceptualize PTG: as an outcome of coping with a stressful life event similar to well-being \[[@CR17]\] or as a process of coping with adversity, which may lead to positive adjustment \[[@CR18]\] but is conceptually distinct from it. Findings regarding the relationships between PTG and well-being in cancer patients have been inconsistent; some studies have found positive (curvilinear) correlations with adjustment outcomes, while others find negative relations or even null findings \[[@CR10], [@CR19]\]. Several hypotheses may explain these inconsistencies including varying PTG levels over time within individuals. However, another possible explanation for these inconsistencies is that PTG may influence well-being not only as a direct effect but also through a stress-buffering mechanism. The ability to identify positive aspects of their cancer experience may help to protect patients from the adverse effects of cancer and its treatment. For example, a study of breast cancer patients showed that PTG moderated relationships between posttraumatic stress (PTS) and both psychological distress and HRQoL \[[@CR20]\]. These authors suggested that PTG may help patients to reinterpret and accept the threatening aspects of the experience, thus restoring a sense of security and lessening the impact of PTS symptoms on well-being.

Prior investigations indicated that 39--48% of AYA cancer patients report PTS symptoms \[[@CR21], [@CR22]\], and that these symptoms negatively impact HRQoL and psychological distress \[[@CR23]\]. It is therefore important to know if PTG is simply an outcome or if it can also act as a stress-buffering process. Considering the gaps in our understanding of PTG among AYAs with cancer, the aims of this study are to (1) examine trajectories of PTG over time, (2) identify the correlates that distinguish PTG trajectories, (3) determine the predictive value of PTG on HRQoL and psychological distress, and (4) examine the buffering role of PTG on the association between PTS and HRQoL and psychological distress. Findings will help health care providers readily identify AYAs who may benefit from targeted interventions that not only aim to reduce psychological distress but also promote positive adaptation and growth.

Methods {#Sec2}
=======

Design, procedure, and patients {#Sec3}
-------------------------------

A prospective, longitudinal, multisite study was conducted to examine HRQoL outcomes over 2 years in AYA patients recently diagnosed with cancer. Baseline data were collected within the first 4 months of diagnosis and subsequently at 6, 12, and 24 months after the baseline survey. The current study focuses on assessments of PTG administered at the three follow-up points. Eligibility criteria included patients aged 14 (and anticipated to turn 15 years old during treatment) through 39 years, with a first diagnosis of any form of invasive cancer, and the ability to read and understand English or Spanish. Participating institutions included three pediatric care institutions and two university-affiliated adult care medical institutions. Research staff at each institution monitored clinic rosters and subsequently identified and approached a total of 286 eligible patients over a 25-month period. Fifty-eight patients did not provide consent, either because they refused participation or because physicians denied access to patients who were too sick to participate. An additional 12 AYAs did not return a completed survey after providing consent, and one died before completing the baseline survey. Overall participation rate was 75% (*n* = 215). Institutional Review Board approval was obtained from each participating site and coordinating center. Informed consent and/or assent was obtained from patients and parents.

Measures {#Sec4}
--------

Posttraumatic growth was measured by the Posttraumatic Growth Inventory (PTGI) \[[@CR24]\] at 6- (T1), 12- (T2), and 24-month (T3) follow-up. Twenty-one items were assessed on a 6-point ordinal scale ranging from 0 (no change at all) to 5 (very great change) for 5 subscales: new possibilities (5 items), relating to others (7 items), personal strength (4 items), spiritual change (2 items), and appreciation of life (3 items). Cancer diagnosis was stated in the question stem as the reference for endorsing items. Scores for each of the five subscales were derived by summing response values, and all items were totaled to determine an overall summated PTGI score, ranging from 0 to 105. Higher scores indicated greater growth. We also computed the proportions of participants endorsing single items at a moderate or great level (item score ≥ 3) to be able to characterize the most common and frequent forms of PTG \[[@CR25]\] and used a cut-off of ≥63 to classify low vs. high PTG levels as was done in previous studies \[[@CR26]--[@CR28]\]. Cronbach's alpha ranged from .84 to .91 for the 5 subscales of the PTGI. Cronbach's α was 0.95 for the overall score.

*Social support* was measured at baseline (T0) with the Medical Outcomes Survey Social Support survey, which is a 19-item questionnaire assessing the degree to which a chronically ill patient perceives availability of functional social support \[[@CR29]\].

*Posttraumatic stress symptoms* were assessed at 6-, 12, and 24-month follow-up using the Posttraumatic Stress Diagnostic Scale (PDS) \[[@CR30]\]. This measure includes 17 questions covering three categories of symptoms: re-experiencing (5 items), avoidance (7 items), and arousal (5 items). We adapted the items in the PDS by replacing the word "trauma" with "cancer" in order to specifically investigate cancer-related PTSS. Item scores are summed to derive an overall posttraumatic stress severity score ranging from 0 to 51.

*Health-related quality of life* (*HRQoL*) was measured at 24-month follow-up (T3) by the Medical Outcomes Study Short Form-36 Health Survey (SF-36) \[[@CR31]\]. Two higher order component scores were calculated, one for physical health (Physical Component Score (PCS)) and one for mental health (Mental Component Score (MCS)). Based on 1998 US population data, raw scores of MCS and PCS are transformed into *T* scores ranging from 0 to 100, with higher scores representing better HRQoL.

*Psychological distress* was assessed at 24-month (T3) follow-up with the Brief Symptom Inventory-18 (BSI-18), which contains 18 self-report items \[[@CR32]\] and comprises a Global Symptom Index (GSI). Raw scores for the GSI were converted to age- and sex-adjusted *T* scores for comparison to non-patient community norms (mean, 50; standard deviation, 10). Higher scores indicate greater distress.

Sociodemographic information, including age, sex, race, employment/school status, and relationship/marital status, was reported by patients. Clinical data obtained from medical charts included type of cancer, types of treatment (chemotherapy, radiation, and surgery), and treatment status (on versus off treatment). Surveillance, Epidemiology, and End Results (SEER) codes were used to categorize cancer type into severity of disease \[[@CR33]\]. In addition, via self-report at baseline and 24-month follow-up, a symptom checklist, derived by the investigators, elicited subject endorsement of 11 common treatment-related side effects during the past month (i.e., shortness of breath; problems with memory, attention, or concentration; frequent or severe stomach pain, pain in your chest (heartburn), or indigestion; ringing in the ears; pain in your joints; weight loss; frequent fevers; lack of sleep or trouble sleeping; frequent tiredness or fatigue; frequent mouth sores that impact eating and drinking; frequent headaches), which were summed and considered in statistical analyses.

Statistical analyses {#Sec5}
--------------------

All statistical analyses were performed using SPSS software, version 22.0 (SPSS Inc., Chicago IL), and two-sided *p* values of \<0.05 were considered statistically significant.

Differences in sociodemographic and clinical characteristics between patients who completed at least two follow-up questionnaires and those who did not were compared with chi-square or ANOVA, where appropriate. Patients who did not complete two follow-up questionnaires were excluded from further analyses.

Descriptive statistics were used to describe the mean PTG overall and subscale scores. Mean differences over time in PTG total and subscale scores were analyzed with paired-sample *t* tests. Thereafter, each respondent was assigned to a PTG trajectory group on the basis of PTGI total scores at each of three time points (6-, 12, and 24-month follow-up). AYAs whose PTG scores were ≥63 \[26--28\] at all three time points were assigned to the high PTG group. Those whose scores exceeded the threshold only at 24-month follow-up, or at 12- and 24-month follow-up, were assigned to the increasing PTG group. Those whose scores exceeded threshold only at 6-month follow-up, or at 6- and 12-month follow-up, were assigned to the decreasing PTG group. AYAs whose scores never reached the threshold were assigned to the low PTG group. Six patients had missing values at 12- or 24-month follow-up and were excluded from analysis.

To examine differences in sociodemographic, clinical, and psychosocial characteristics between the four groups, chi-square or ANOVA was used, where appropriate.

To determine the predictive and buffering value of PTG, three multiple hierarchical linear regression equations were estimated, one for each outcome (mental HRQoL, physical HRQoL, psychological distress), in four separate steps: (1) the control variables previously correlated at a significant level (*p* \< 0.10) with the outcome measures, (2) adding PTS (mean centered), (3) adding PTG (mean centered), and (4) adding the interaction term PTS × PTG.

Results {#Sec6}
=======

Characteristics of the study population {#Sec7}
---------------------------------------

The demographic and clinical characteristics of 169 participants who completed at least two follow-up surveys are summarized in Table [1](#Tab1){ref-type="table"}. Of the 46 non-respondents, 28 were deceased (60.9%). Respondents were younger, more often received chemotherapy, and were on treatment at baseline compared to non-respondents and deceased patients. Non-respondents had a better overall survival expectation (based on 5-year survival data for each specific cancer type) compared to respondents.Table 1Sample characteristicsRespondents with at least 2 follow-up questionnaires completed\
*N* = 169 (78.6%)^a^Non-respondents at follow-up\
*N* = 18 (8.4%)Deceased at follow-up\
*N* = 28 (13.0%)*p* valueSex0.09 Female77 (45.6%)6 (33.3%)18 (64.3%) Male92 (54.4%)12 (66.7%)10 (35.7%)Race0.58 White77 (46.1%)7 (38.9%)11 (39.3%) Hispanic/Latino72 (43.1%)8 (44.4%)11 (39.3%) Other18 (10.8%)3 (16.7%6 (21.4%)Relationship status^b^0.13 No108 (65.1%)8 (44.4%)14 (51.9%) Yes58 (34.9%)10 (55.6%)13 (48.1%)Educational level0.06 Less than high school86 (51.5%)6 (33.3%)10 (35.7%) High school graduate22 (13.2%)4 (22.2%)5 (17.9%) Some college34 (20.4%)7 (38.9%)4 (14.3%) College graduate or above25 (15.0%)1 (5.6%)9 (32.1%)Employment/school status0.90 Not occupied^c^98 (59.0%)10 (55.6%)15 (62.5%) Occupied^d^68 (41.0%)8 (44.4%)9 (37.5%)Age at diagnosis, years0.012 Mean (SD) 14--1779 (46.7%)4 (22.2%)5 (17.9%) 18--2533 (19.5%)3 (16.7%)7 (25.0%) 26--3957 (33.7%)11 (61.1%)16 (57.1%)Type of cancer0.003 Breast carcinoma15 (8.9%)1 (5.6%)3 (10.7%) Hodgkin lymphoma20 (11.8%)3 (16.7%)0 (0%) Non-Hodgkin lymphoma13 (7.7%)2 (11.1%)2 (7.1%) Testicular carcinoma8 (4.7%)5 (27.8%)1 (3.6%) Female reproductive3 (1.8%)2 (11.1%)3 (10.7%) Soft tissue sarcoma19 (11.2%)0 (0%)2 (7.1%) Brain13 (7.7%)0 (0%)1 (3.6%) Leukemia44 (26.0%)1 (5.6%)5 (17.9%) Bone tumors21 (12.4%)1 (5.6%)4 (14.3%) Other carcinomas^e^13 (7.7%)3 (16.7%)7 (25.0%)Severity of cancer by survival rate0.03 \<50%53 (31.4%)1 (5.6%)9 (32.1%) 50--80%68 (40.2%)6 (33.3%)13 (46.4%) \>80%48 (28.4%)11 (61.1%)6 (21.4%)Type of treatment Receiving chemotherapy147 (87.0%)9 (52.9%)19 (67.9%)\<0.001 Receiving radiation29 (17.2%)5 (29.4%)3 (10.7%)0.27 Surgical treatment51 (30.2%)4 (23.5%)11 (39.3%)0.50Treatment status baseline0.017 Off treatment9 (5.3%)4 (22.2%)4 (14.3%) On treatment160 (94.7%)14 (77.8%)24 (85.7%)^a^For some variables, the sum of number is not 169 because of missing data^b^Question was worded as follows: "Are you currently married, living together, or in a significant committed relationship?"^c^Response categories included the following: on temporary medical leave/disability, unemployed, and permanently unable to work^d^Response categories included the following: employed full time, employed part time, full-time homemaker, and full-time student^e^Other carcinomas included thyroid, melanoma, adrenocortical carcinoma, hepatic carcinoma, colorectal carcinoma, head and neck cancer, and other sarcoma

Posttraumatic growth {#Sec8}
--------------------

The average PTG total and subscale scores at each follow-up point are shown in Fig. [1](#Fig1){ref-type="fig"}. At T1, 59% scored high on PTG, while 64% at T2 and 58% at T3 scored ≥63. At 6-month follow-up, all AYAs reported at least one form of PTG, while at 12- and 24-month follow-up all but one AYA reported some form of PTG. The most frequently endorsed items were "An appreciation for the value of my own life" (83--87%), "Knowing I can handle difficulties" (77--81%), "Knowing that I can count on people in times of trouble" (72--86%), "Appreciate each day" (78--80%), "I discovered that I\'m stronger than I thought I was" (69--81%), "I learned a great deal about how wonderful people are" (70--80%), and "My priorities about what is important in life" (71--73%). Paired-sample *t* tests showed no significant changes in PTG total scores or subscales over time but identified two subscales showing significant change: spiritual change (e.g., "I have a stronger religious faith") which increased from 6 to 12 months (*p* = 0.006) and personal strength (e.g., "I discovered that I am stronger than I thought I was") which improved from 6 to 12 months (*p* = 0.001) and 6 to 24 months (*p* = 0.003).Fig. 1Mean PTG subscale scores at each time point. *T1* 6-month follow-up, *T2* 12-month follow-up, *T3* 24-month follow-up

Among participants, 73 (45%) had high levels of PTG at all three time points (84, 83, and 86%, respectively), 23 (14%) had decreasing PTG levels (70, 64, and 42%, respectively), 23 (14%) had increasing PTG levels (48, 67, and 80%, respectively), and 44 (27%) had low PTG levels at all time points (38, 42, and 34%, respectively; Fig. [2](#Fig2){ref-type="fig"}).Fig. 2PTG trajectories over time. *T1* 6-month follow-up, *T2* 12-month follow-up, *T3* 24-month follow-up

Correlates {#Sec9}
----------

Participants who had high scores on PTG at each time point were more often female, younger, and receiving chemotherapy compared to the other three groups (low PTG, increasing PTG, decreasing PTG; Table [2](#Tab2){ref-type="table"}). No differences between the groups were found in other sociodemographic and cancer-related factors.Table 2Demographic, clinical, and psychosocial characteristics of patients according to their PTG levels over timeHigh PTG\
*N* = 73 (44.8%)Increasing PTG\
*N* = 23 (14.1%)Low PTG\
*N* = 44 (27.0%)Decreasing PTG\
*N* = 23 (14.1%)*p* valueSociodemographic and clinical characteristicsSex0.011 Female43 (58.9%)9 (39.1%)18 (40.9%)5 (21.7%) Male30 (41.1%)14 (60.9%)26 (59.1%)18 (78.3%)Race0.82 White31 (43.1%)10 (43.5%)21 (47.7%)13 (59.1%) Hispanic/Latino33 (45.8%)11 (47.8%)17 (38.6%)8 (36.4%) Other8 (11.1%)2 (8.7%)6 (13.6%)1 (4.5%)Relationship status over time0.29 Relationship at all time points16 (21.9%)5 (21.7%)7 (15.9%)8 (36.4%) No relationship at any time point38 (52.1%)13 (56.5%)29 (65.9%)7 (31.8%) Fluctuating19 (26.0%05 (21.7%)8 (18.2%)7 (31.8%)Educational level 24-month follow-up0.064 Less than high school28 (51.9%)6 (31.6%)10 (26.3%)3 (17.6%) High school graduate10 (18.5%)5 (26.3%)8 (21.1%)3 (17.6%) Some college8 (14.8%)4 (21.1%)11 (28.9%)9 (52.9%) College graduate or above8 (14.8%)4 (21.1%)9 (23.7%)2 (11.8%)Occupational status over time0.67 Job/school at all time points34 (47.2%)8 (34.8%)17 (38.6%)7 (30.4%) No job/school at any time point15 (20.8%)7 (30.4%)8 (18.2%)6 (26.1%) Fluctuating23 (31.9%)8 (34.8%)19 (43.2%)10 (43.5%)Age at diagnosis, years Mean (SD)21.9 (8.9)23.7 (9.0)22.2 (8.6)27.7 (8.8)0.046 14--1741 (56.2%)10 (43.5%)21 (47.7%)3 (13.0%)0.009 18--258 (11.0%)4 (17.4%)11 (25.0%)9 (39.1%) 26--3924 (32.9%)9 (39.1%)12 (27.3%)11 (47.8%)Severity of cancer by survival rate0.78 \<50%24 (32.9%)8 (34.8%)16 (36.4%)4 (17.4%) 50--80%27 (37.0%)9 (39.1%)17 (38.6%)10 (43.5%) \>80%22 (30.1%)6 (26.1%)11 (25.0%)9 (39.1%)Type of treatment (cumulative)0.034 Receiving chemotherapy70 (100%)21 (91.3%)39 (88.6%)20 (87.0%)0.82 Receiving radiation16 (26.2%)6 (28.6%)8 (20.0%)6 (35.3%)0.58 Surgical treatment44 (65.7%)15 (75.0%)26 (63.4%)17 (85.0%)Treatment status over time0.29 On treatment at all time points16 (21.9%)5 (21.7%)7 (15.0%)8 (36.4%) Off treatment at all time points38 (52.1%)13 (56.5%)29 (65.9%)7 (31.8%) Fluctuating19 (26.0%)5 (21.7%)8 (18.2%)7 (31.8%)Number of symptoms baseline0.34 Mean5.5 (2.4)4.6 (3.0)4.9 (2.4)4.8 (2.8)Number of symptoms 24-month follow-up0.81 Mean (SD)3.0 (2.9)2.9 (2.3)3.4 (2.7)2.7 (2.6)Total social support baseline mean (SD)82.2 (15.6)75.9 (18.9)79.1 (14.8)80.4 (16.1)0.40

Association between PTG and HRQoL and psychological distress {#Sec10}
------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} summarizes the results of the hierarchical regression equations performed. Results show that PTG level at 6-month follow-up is predictive of mental HRQoL (*β* = 0.19; *p* = 0.026) and psychological distress (*β* = −0.14; *p* = 0.043) at 24-month follow-up when corrected for PTS at 6-month follow-up and covariates which were related to the outcomes on bivariate level. No relationship between PTG and physical HRQoL was found. Note that PTS also remained a significant predictor of mental HRQoL and psychological distress (Table [3](#Tab3){ref-type="table"}).Table 3Final hierarchical regression analysis of PTG × PTS interaction at 6-month follow-up on HRQoL and psychological distress at 24-month follow-up*β*Mental HRQoL (MCS) Treatment status (off treatment)0.25\*\* Occupational status\
(not at school/job)−0.20\* Social support0.05 Symptoms at 24-month follow-up−0.18\* PTS at 6-month follow-up−0.42\*\* PTG at 6-month follow-up0.19\* PTS × PTG−0.07  *F*9.26\*\*  *R* ^2^0.42Physical HRQoL (PCS) Occupational status\
(not at school/job)−0.11 Social support0.13 Symptoms at 24-month follow-up−0.38\*\* PTS at 6-month follow-up−0.13 PTG at 6-month follow-up0.04 PTS × PTG0.11  *F*5.57\*\*  *R* ^2^0.27Psychological distress Treatment status (off treatment)−0.16\* Occupational status (not at school/job)0.09 Social support−0.13 Symptoms at 24-month follow-up0.35\*\* PTS at 6-month follow-up0.48\*\* PTG at 6-month follow-up−0.14\* PTS × PTG−0.12  *F*17.14\*\*  *R* ^2^0.56\**p* \< 0.05; \*\**p* \< 0.01

Buffering effect of PTG on link between PTS and HRQoL and psychological distress {#Sec11}
--------------------------------------------------------------------------------

Results revealed no significant interaction effects between PTS and PTG on outcomes, indicating that buffering did not take place (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec12}
==========

In this prospective follow-up study, we found that most AYAs with cancer experience some degree of PTG between 6 and 24 months after baseline assessment. In accordance with the literature, the most frequently scored PTGI items included a sense of enhanced life appreciation, reinforced interpersonal relationships, and personal strengthening, whereas finding new opportunities and spiritual change were the least endorsed areas of growth \[[@CR25]--[@CR27], [@CR34], [@CR35]\]. Our study adds to the current literature by showing that PTG is a dynamic process within individuals. Although no significant mean differences in PTG scores were found over time within the sample as a whole, we were able to identify four trajectories of individual change or stableness: high PTG, increasing PTG, decreasing PTG, and low PTG. Interestingly, the number of individuals who showed increasing PTG over time approximately matched those who showed decreasing PTG. A major goal for future work should be increasing the prevalence of increasing PTG profiles.

When looking at factors promoting or preventing PTG in different studies, our findings show that females, younger AYAs, and those who received chemotherapy more often were found in the high PTG group and least often in the low PTG group. Some researchers have suggested that women are, on average, more emotion-focused in their coping strategies and may therefore be more often able than men to derive a sense of positive meaning from the traumatic experience of cancer \[[@CR10], [@CR36]\]. Younger patients might be more aware of and motivated to conform to expectations to adopt a positive attitude in the face of cancer than are older patients \[[@CR27], [@CR37]\]. It may also be that a cancer diagnosis is more stressful and necessitates more developmental readjustment for younger AYAs \[[@CR10]\], leading to more PTG. The other way around, the impact of cancer on younger AYAs is happening at a time when most of them still have support of their family/parents, they are just starting out on life, have not yet gained (financial) independence or are still reliant on parents, and do not have children or families of their own to worry about whilst those who are diagnosed as older AYAs may have all these responsibilities of having a job, family, and mortgage, which may potentially make a cancer diagnosis more life disrupting and may limit them to find benefit of their cancer experience. It could also be that older AYAs are more aware of what a cancer diagnosis may mean for them in terms of their health and their future. One might also hypothesize that receipt of more aversive treatments that produce greater life disruption (e.g., chemotherapy) might set the stage for greater PTG \[[@CR10]\]; however, studies have demonstrated no association between chemotherapy and PTG \[[@CR20], [@CR26], [@CR35]\].

Findings to date regarding PTG following a cancer diagnosis have been quite inconsistent regarding relationships with well-being; PTG is sometimes shown to be positively related to adjustment to cancer, but sometimes inversely, and often with little relationship at all \[[@CR10], [@CR19]\]. We found a direct positive predictive effect of PTG on mental HRQoL and a direct negative predictive effect on psychological distress. This suggests that PTG may reflect a cognitive adaptation process in response to a cancer diagnosis \[[@CR19], [@CR20]\], helping the AYAs to better mentally adjust to the cancer experience. PTG may provide a positive engagement with life, strengthening peoples' feelings of self-reliance and fostering social relationships \[[@CR38]\], which may explain these direct relationships. On the other hand, PTG was not a predictor of physical HRQoL. It seems that this outcome is more influenced by the physical symptoms AYAs are currently coping with than by PTG. One explanation for the lack of this relationship could be that PTGI measures psychosocial areas of growth and not physical domains \[[@CR39]\]. Future research could explore the predictive value of physical HRQoL for PTG.

Inconsistent with previous research identifying PTG as a buffer against the harmful effects of PTS \[[@CR34], [@CR40]\], PTG did not interact with PTS to predict these outcomes in our study. It could be hypothesized that PTS and PTG consist of different processes which may co-exist but are largely independent \[[@CR13], [@CR26], [@CR27], [@CR41]\]. PTG reflects a coping process or resource that triggers the cognitive reconstruction of the individual's beliefs and strengths, while PTS is more an emotional process of intrusive thoughts, avoidance behavior, and heightened arousability with an aversive nature \[[@CR42]\]. However, there is one study showing that re-experiencing trauma (a symptom of PTS) has a curvilinear relationship with two scales of the PTGI (new possibilities and personal strengths), showing that re-experiencing may also represent a cognitive process necessary to achieve personal growth for AYAs \[[@CR13]\]. The authors state that opportunities to engage family, friends, cancer survivors, or health care professionals in frank discussions about fears, worries, or concerns may help AYAs re-experience cancer in a way that enhances their understanding of what happened to them and contributes to better mental well-being.

One potential implication of these findings is that helping AYAs with cancer who experience low or decreasing levels of PTG find meaning and benefits in the cancer experience may help improve their mental adjustment. This may be accomplished by encouraging the reappraisal of the situation (positive reframing) or the emotional disclosure of inner feelings and fears \[[@CR43]\]. A written emotional disclosure intervention, whereby adult breast cancer survivors were randomized to write about positive thoughts and feelings related to their cancer, showed that those who wrote down positive feelings reported less physician visits for medical comorbidities and distress than survivors who wrote down facts of their experience \[[@CR43]\]. In addition, two cognitive-behavioral interventions among adult cancer patients, that included elements of coping skills training, relaxation exercises, conflict resolution, and emotional expression, had beneficial effects on PTG \[[@CR44], [@CR45]\]. Another way to enhance PTG may be regular physical activity. The physiological benefit of physical activity may be stress reduction. Physical activity may also increase levels of social support for AYA cancer patients and serve as an active coping strategy to decrease levels of distress \[[@CR15]\]. In addition, physical activity can improve AYA cancer patients' self-efficacy levels, whereby the experience of positive feelings may be enhanced. As PTG predicts mental well-being, interventions focused on improving PTG are likely beneficial in the early post-treatment period.

This study is limited by the fact that PTG trajectory group sizes were too small to conduct multivariate linear regression on outcomes. Therefore, we used mean-centered continuous PTG scores at 6-month follow-up to predict outcomes at 24-month follow-up. Longitudinal mixed model analyses were not conducted because of the lack of HRQoL data at 6-month follow-up. Furthermore, with regard to instrumentation, the current study relied upon generic instruments with limited evidence of validity and reliability in study samples consisting of persons under 18 years of age. In addition, we did not assess social desirability. Some cancer patients believe they should derive growth from their cancer experience and subsequently may report such growth regardless of their personal experience of positive change or benefit \[[@CR41]\]. Similarly, some cancer patients know thinking and talking positively about their cancer experience will elicit positive attention from others \[[@CR46]\]. Future research is needed to examine the meaning of PTG for AYAs in the broader contexts of their lives and the ways in which they process their experiences. For example, the four PTG trajectories could indicate that PTG functions as a coping style early after diagnosis but becomes real growth for some after a longer period of time \[[@CR47]\].

In conclusion, this study shows that PTG is a dynamic process within the individual AYA cancer patient that predicts mental well-being outcomes but does not serve to buffer PTS. Psychosocial interventions should focus on both PTS and PTG in order to promote positive adjustment for AYAs diagnosed with cancer.
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